Anna Podolanczuk, MD

Highlights

1
The European respiratory journal · 2023
APAnna Podolanczuk
PMID: 36702498DOIFirst author369 citations
2
American journal of respiratory and critical care medicine · 2022
APAnna Podolanczuk
PMID: 34929108PMCID: PMC10394677DOISenior author32 citations
3
Thorax · 2022
APAnna Podolanczuk
PMID: 36690926PMCID: PMC9899287DOISenior author21 citations

Publications

108

Funding

10 View NIH portfolio on RePORTER ↗

Active

7 grants

PI
Multi-omic profiling of pulmonary fibrosis and cardiovascular disease
National Heart, Lung, and Blood Institute · 2026–2031
R01HL185515-01
PI
Retrospective EValuation in US of e-Lung in PPF - REVISE PPF
Brainomix · 2024–2029Contract
SRA 245118-01
Sub-PI
Metformin to Attenuate ProgressiVe RespIratory Decline in Idiopathic Pulmonary Fibrosis (MAVRIC-IPF)
U.S. Department of Defense · 2025–2029 · via University of Massachusetts Medical School
HT9425-25-1-0982
Sub-PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
National Heart, Lung, and Blood Institute · 2024–2027 · via University of Massachusetts Medical School
R33HL158540-04
MPI
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study
National Heart, Lung, and Blood Institute · 2021–2027 · via The Regents of the University of Michigan
U24HL145265-06
Sub-PI
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis (MAVRIC-IPF)
U.S. Department of Defense · 2025–2026 · via University of North Carolina at Chapel Hill
HT9425-25-1-0982
Sub-PI
Phase II: B4PF Imaging Initiative
Three Lakes Foundation · 2023–2025 · via Vanderbilt University Medical Center
VUMC 240491-01

Completed grants (3)

PI
Role of High Density Lipoproteins in Interstitial Lung Disease
National Heart, Lung, and Blood Institute · 2020–2024Career
K23HL140199-04
Co-I
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients
National Heart, Lung, and Blood Institute · 2022–2024
R61HL158540-01A1
PI
B4PF Imaging Initiative
Three Lakes Foundation · 2022–2023
TLF 225482-01

Clinical research

Active

8 studies

PI
A Multinational, Long-Term, Safety and Tolerability, Open-Label Extension Study of Subjects Who Have Participated in Avalyn Pharma Studies of Inhaled Antifibrotic Agents (AP-LTE-008 [SAIL])
PHASE2 · Avalyn Pharma, Inc. · OPEN TO ACCRUAL (as of 2026)
Progressive Pulmonary Fibrosis; Idiopathic Pulmonary Fibrosis (IPF)
NCT06951217
PI
Multi-omic Profiling of pulmonary fibrosis and cardiovascular disease
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)
PI
A Double Blind, Randomized, Placebo-controlled Exploratory Trial to Investigate the Efficacy and Safety of Nerandomilast Over 24 Months When Administered in Individuals With Interstitial Lung Abnormalities and a Family History of Pulmonary Fibrosis to Reduce the Risk of Worsening (DROP-FPF)
PHASE3 · Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · OPEN TO ACCRUAL (as of 2026)
Familial Pulmonary Fibrosis; Interstitial Lung Abnormalities; Interstitial Lung Diseases
NCT07201922
PI
Evaluating pulmonary fibrosis with optical coherence tomography: Pilot Study
The General Hospital Corporation (dba Massachusetts General Hospital) · OPEN TO ACCRUAL (as of 2026)
PI
An Open-label Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease (TETON-OLE)
PHASE3 · United Therapeutics · OPEN TO ACCRUAL (as of 2025)
Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease; Progressive Pulmonary Fibrosis
NCT04905693
PI
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF
PHASE2 · Avalyn Pharma, Inc. · OPEN TO ACCRUAL (as of 2024)
Pulmonary Fibrosis; Progressive Pulmonary Fibrosis; Pulmonary Fibrosis Secondary to Systemic Sclerosis; Pulmonary Fibrosis, Interstitial Lung Disease; Interstitial Lung Disease; Interstitial Lung Disease Due to Connective Tissue Disease (Disorder); Interstitial Lung Disease in Patients With Rheumatoid Arthritis; Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere; Hypersensitivity Pneumonitis; Interstitial Lung Disease With Systemic Sclerosis
NCT06329401
PI
A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
PHASE3 · United Therapeutics · OPEN TO ACCRUAL (as of 2024)
Progressive Pulmonary Fibrosis; Interstitial Lung Disease
NCT05943535
PI
Exosome Profiling to Reveal Circulating Protein Biomarkers of Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease
Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2022)

Completed & closed trials (7)

PI
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial
PHASE3 · University of Massachusetts Medical School · IRB STUDY CLOSURE (as of 2026)
Idiopathic Pulmonary Fibrosis
NCT04300920
PI
A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
PHASE2 · GlaxoSmithKline · IRB STUDY CLOSURE (as of 2026)
Idiopathic Pulmonary Fibrosis
NCT06317285
PI
A Randomized, Double-blind, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy and Safety of Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis (BEACON-IPF)
PHASE2 · Pliant Therapeutics, Inc · IRB STUDY CLOSURE (as of 2026)
Idiopathic Pulmonary Fibrosis
NCT06097260
PI
Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect
PHASE1 · University of California, San Francisco · CLOSED TO ACCRUAL (as of 2025)
Idiopathic Pulmonary Fibrosis
NCT05195918
PI
Retrospective EValuation in US of e-Lung in PPF
Brainomix · CLOSED TO ACCRUAL (as of 2025)
PI
PFF Registry Ancillary Study: Role of High Density Lipoproteins in Interstitial Lung_x000D_ Disease
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2022)
PI
Household Dust Microbiome and Idiopathic Pulmonary Fibrosis
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2021)

External relationships

Advisory/Scientific Board Member

Avalyn Pharma, Inc. · Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · Brainomix · Nelum Pharmaceuticals · PureTech Health · Three Lakes Foundation · United Therapeutics

Speaker/Lecturer

BTIG, LLC · PeerDirect

Other Interest

Trevi Therapeutics

Other

Boehringer Ingelheim Pharmaceuticals, Inc. (USA) · EBSCO · Eisai, Inc. · Imvaria Inc. · Pliant Therapeutics, Inc · PureTech Health · Regeneron Pharmaceuticals, Inc. · Roche Pharmaceuticals, Inc. · Veracyte, Inc.